Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) [Phase 3]

View source ↗

Summary

A Phase 3 trial to evaluate the efficacy and safety of subcutaneous anifrolumab added to standard of care versus placebo with standard of care in adults with po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Polymyositis

Drugs mentioned

• Anifrolumab (anifrolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Polymyositis, Dermatomyositis | Phase 3 | Status: RECRUITING